CovalX

Name: CovalX
Address: Schützengasse 23, Zürich, CH-8001, CH
Telephone: +16172972263

CovalX AG is a Zürich, Switzerland-based company which develops and manufactures scientific instrumentation for academic research and industrial use.

The companies products are focused on measuring intact protein complexes by MALDI mass spectrometry.

12/06/2026

Methods and Compositions for Screening And Detecting Biomarkers https://hubs.ly/Q04kM-Xc0

This article discusses the integration of monoclonal antibody (mAb) mechanisms of action into the IMGT/mAb-DB database. This comprehensive resource provides detailed insights into mAb structures, functions, and therapeutic targets, facilitating a deeper understanding of their roles in oncology and other fields.

At CovalX, our mAb Characterization Services complement such databases by offering high-resolution mass spectrometry analyses to elucidate antibody structures, binding interactions, and functional properties. By combining curated data with experimental characterization, we support researchers in advancing antibody-based therapeutics.

11/06/2026

Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB https://hubs.ly/Q04kN69R0

The article in Frontiers in Immunology presents an updated classification of the mechanisms of action (MOA) for monoclonal antibodies (mAbs) in oncology, highlighting how their structural components influence immune modulation and therapeutic function. By mapping these MOAs in the IMGT/mAb-DB, the study advances our understanding of mAb functionality and supports precision drug design.

At CovalX, our mAb Characterization Services help researchers decode these complex antibody mechanisms through advanced mass spectrometry, ensuring reliable data for therapeutic development.

10/06/2026

Switching Anti-CGRP Monoclonal Antibody Therapy in Nonresponders with Migraine May Reduce Monthly Headache Days https://hubs.ly/Q04kP1WS0

A recent study suggests that switching anti-CGRP monoclonal antibody (mAb) therapies may benefit migraine patients who don't respond to their initial treatment, leading to fewer monthly headache days. This highlights the importance of understanding mAb therapeutic behavior and individual responses.

At CovalX, our mAb Characterization Services provide precise mass spectrometry tools to help researchers and developers optimize and differentiate mAb therapies for improved outcomes.

21/05/2026

Dendrimer Conjugates with PD-L1-Binding Peptides Enhance In Vivo Antitumor Immune Response https://hubs.ly/Q04hcZf50

A recent study introduced dendrimer conjugates functionalized with PD-L1-binding peptides that significantly enhanced tumor targeting, binding avidity, and in vivo antitumor immune responses. By leveraging multivalent dendrimer-peptide interactions, the platform demonstrated improved PD-L1 blockade efficiency, prolonged circulation, and selective tumor accumulation, highlighting a promising strategy for next-generation cancer immunotherapy.

Importantly, the study utilized MALDI-TOF mass spectrometry for characterization of the dendrimer-peptide conjugates, underscoring the critical role of advanced high-mass MS technologies in complex biologic analysis. At CovalX, our High-Mass MALDI-MS service provides high-resolution characterization of large biomolecules, protein assemblies, and therapeutic conjugates, helping researchers gain precise molecular insights to accelerate biotherapeutic development. https://hubs.ly/Q04hcLZQ0

20/05/2026

Ensemble machine learning algorithms leveraged on serum proteomics for enhanced early detection of ovarian cancer https://hubs.ly/Q04hbfK30

A recent study demonstrated how advanced mass spectrometry approaches can reveal detailed molecular and structural insights into complex biomolecular systems, highlighting the increasing importance of high-resolution analytical technologies in modern biological research. The work underscores how sensitive MS-based characterization supports deeper understanding of protein interactions, structural heterogeneity, and biomolecular function.

At CovalX, our High-Mass MALDI-MS service enables precise characterization of large biomolecules, protein complexes, and high-molecular-weight assemblies that are often difficult to analyze using conventional techniques. With advanced high-mass detection capabilities, CovalX helps researchers generate high-confidence structural and molecular insights to support biotherapeutic development and complex biological investigations. https://hubs.ly/Q04h9RxG0

19/05/2026

Accelerated Direct Identification of Gram-Positive and Gram-Negative Bacteria Using Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) in Critically Ill Patients https://hubs.ly/Q04h9vDH0

A recent study demonstrated how MALDI-TOF mass spectrometry enables rapid direct identification of Gram-positive and Gram-negative bacteria in critically ill patients, significantly accelerating diagnostic workflows and supporting faster clinical decision-making. The research highlights the growing role of MALDI-based technologies in delivering high-throughput, sensitive analysis of complex biological samples.

At CovalX, our High-Mass MALDI-MS service extends these analytical capabilities to the characterization of large biomolecules, protein complexes, and biotherapeutics. Using advanced high-mass detection technologies, CovalX helps researchers generate high-confidence molecular insights for challenging high-molecular-weight systems.

15/05/2026

Thank you to everyone who visited the CovalX Booth #220 at PEGS Boston 2026! We look forward to continuing the conversations and collaborations ahead. https://hubs.ly/Q04gPMRH0

It was a pleasure connecting with so many scientists, collaborators, and industry innovators throughout the week. From discussing epitope mapping, HDX-MS and de novo sequencing analysis to sharing insights on advanced mass spectrometry solutions, we appreciated the engaging conversations and interest in CovalX biotherapeutic technologies.

We’re grateful for the opportunity to showcase how CovalX continues to support cutting-edge biologics research and drug discovery. Thank you for making PEGS Boston 2026 successful event for our team!

13/05/2026

Discovery of Anti-SARS-CoV-2 XBB.1.5 and JN.1 Variant-Specific Monoclonal Single-Domain Antibodies from a Synthetic Library https://hubs.ly/Q04gjqQv0

Recent research describes the discovery of single-domain antibodies (sdAbs) capable of selectively recognizing SARS-CoV-2 XBB.1.5 and JN.1 variants from a synthetic antibody library, demonstrating a promising strategy for targeting rapidly evolving viral strains. Using advanced structural and binding analyses, the study identified critical epitope regions involved in variant-specific recognition, offering valuable insight for next-generation antiviral therapeutic development.

At CovalX, our HDX-MS Epitope Mapping service provides high-resolution characterization of antibody–antigen interaction sites and conformational dynamics, helping researchers precisely define binding epitopes and accelerate therapeutic antibody discovery. By delivering detailed structural insights, CovalX supports the development of more targeted and effective biologics. https://hubs.ly/Q04gl8hs0

12/05/2026

Discovery and Characterization of Two anti-PD-1 Antibodies with a Unique Binding Mechanism to human PD-1 https://hubs.ly/Q04gcR4t0

Recent research describes the discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism, offering new insights into immune checkpoint targeting for cancer immunotherapy. By revealing distinct interaction modes with the PD-1 receptor, the study highlights how detailed epitope and structural analysis can guide the development of more selective and potentially effective therapeutic antibodies.

At CovalX, our Epitope Mapping services leverage advanced mass spectrometry technologies, including HDX-MS and XL-MS, to precisely characterize antibody-antigen interaction sites and conformational dynamics. These high-resolution insights help researchers better understand mechanisms of action and accelerate the development of next-generation immunotherapies.

11/05/2026

PEGS Boston 2026 starts today! https://hubs.ly/Q04g8Lwx0

The CovalX team is excited to be attending the Protein & Antibody Engineering Summit in Boston this week from May 11-15, 2026 at the Omni Boston Hotel at the Seaport, Boston, MA,. If you’re at the event, stop by Booth #220 to learn more about our advanced mass spectrometry solutions for biotherapeutic characterization, epitope mapping, de novo sequencing, and more.

We look forward to connecting with researchers, collaborators, and innovators throughout the conference!

Adresse

Schützengasse 23
Zürich
CH-8001

Telefon

+16172972263

Webseite

https://covalx.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von CovalX erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.